The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Single agent versus combination chemotherapy for metastatic breast cancer
Open accessAbstract
BACKGROUND: Combination chemotherapy regimens are frequently favoured over single agents for the treatment of metastatic breast cancer, in an attempt to achieve superior tumour response rates. It is not known however whether giving more intensive chemotherapy regimens results in better health outcomes, when both survival and toxicity are considered, and whether better response rates and rates of progression free survival actually translate to better overall survival. OBJECTIVES: To compare single agent with combination chemotherapy for the treatment of metastatic breast cancer. SEARCH STRATEGY: We searched the Cochrane Breast Cancer Group Specialised Register November 2008. Handsearching of recent conference proceedings was also undertaken. SELECTION CRITERIA: Randomised trials of single agent chemotherapy compared to combination therapy in metastatic breast cancer. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trials for eligibility and quality, and extracted data. Hazard ratios were derived for reported time-to-event outcomes.Response rates were analysed as dichotomous variables. Toxicity and quality of life data were extracted where present. MAIN RESULTS: Forty three eligible trials (48 comparisons) were identified. These included 9742 women, 55% of whom were receiving first-line treatment for metastatic disease. For overall survival there was a statistically significant difference in favour of the combination regimens with no heterogeneity (HR 0.88, 95% CI 0.83-0.93, p<0.00001). Results were very similar when trials of first-line treatment were analysed, and for analyses where the single agent was also included in the combination regimen. Combination regimens showed a statistically significant advantage for survival over single agent taxane (HR 0.82; 95% CI 0.75-0.89, p<0.00001), but not anthracycline (HR 0.94.86-1.02, p=0.15).Combination regimens were also associated with significantly better time to progression (HR 0.78, 95% CI 0.74 - 0.82, p<0.00001) and response (RR 1.29, 95% CI 1.14 -1.45, p<0.0001) although heterogeneity was statistically significant in both instances and probably due to clinical diversity of the participants and interventions.Women receiving combination regimens experienced a statistically significant detrimental effect on white cell count, increased alopecia and nausea and vomiting. AUTHORS' CONCLUSIONS: Combination chemotherapy regimens show a statistically significant advantage for survival, tumor response and time to progression in women with metastatic breast cancer but they also produce more toxicity. An unresolved question is whether combination regimens are more effective than single agents given sequentially.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Self-citationParmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Sledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 707
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Fossati, R., Confalonieri, C., Torri, V, Ghislandi, E., Penna, A., Pistotti, V, Tinazzi, A., & Liberati, A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3439 · Cited by 546
Nabholtz, J.-M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschênes, L., Douma, J., Vandenberg, T. A., Rapoport, B., Rosso, R., Trillet-Lenoir, V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1413 · Cited by 508
Thomas, E. S., Gomez, H. L., Li, R. K., Chung, H.-C., Fein, L. E., Chan, V. F., Jassem, J., Pivot, X. B., Klimovsky, J. V., de Mendoza, F. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.6557 · Cited by 481
Thomas, E. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5019 · Cited by 428
O’Shaughnessy, J. A., Blum, J., Moiseyenko, V., Jones, S. E., Miles, D., Bell, D., Rosso, R., Mauriac, L., Osterwalder, B., Burger, H.-U., et al. (2001) · Annals of Oncology · doi:10.1023/a:1012281104865 · Cited by 304
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
Crown, J., O'Leary, M., & Ooi, W.-S. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_2-24 · Cited by 249
Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.
Hryniuk, W. M., Figueredo, A. T., & Goodyear, M. D. E. (1987) · PubMed · Cited by 227
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
Stockler, M., Wilcken, N. R. C., Ghersi, D., & Simes, R. J. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0161 · Cited by 218
Self-citationKeller, A. M., Mennel, R. G., Georgoulias, V. A., Nabholtz, J.-M., Erazo, A., Lluch, A., Vogel, C. L., Kaufmann, M., von Minckwitz, G., Henderson, I. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.157 · Cited by 214
Bishop, J. F., Dewar, J., Toner, G. C., Smith, J., Tattersall, M. H. N., Olver, I. N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2355 · Cited by 209
Martín, M., Ruiz, A., Muñoz, M., Balil, A., García-Mata, J., Calvo, L., Carrasco, E., Mahillo, E., Casado, A., García-Saenz, J. Á., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70041-4 · Cited by 187
Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer
Wilcken, N., Hornbuckle, J., & Ghersi, D. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002747 · Cited by 165
Self-citationAlbain, K. S., Nag, S., Calderillo-Ruiz, G., Jordaan, J. P., Llombart‐Cussac, A., Pluzanska, A., Pawlicki, M., Melemed, A. S., O’Shaughnessy, J., & Reyes, J. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.510 · Cited by 161
Joensuu, H., Holli, K. A., Heikkinen, M., Suonio, E., Aro, A. R., Hietanen, P. S., & Huovinen, R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3720 · Cited by 151
Cardoso, F., Leo, A. D., Lohrisch, C. A., Bernard, C., Ferreira, F., & Piccart, M. J. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf101 · Cited by 146
Single agent versus combination chemotherapy for metastatic breast cancer
Carrick, S. E., Parker, S., Thornton, C. E., Ghersi, D., Simes, J. R., & Wilcken, N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003372.pub2 · Cited by 118
Self-citationAchievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Colozza, M., de Azambuja, E., Personeni, N., Lebrun, F., Piccart, M. J., & Cardoso, F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-253 · Cited by 97
Goals of Treatment for Patients With Metastatic Breast Cancer
Smith, I. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.030 · Cited by 87
Berruti, A., Bitossi, R., Gorzegno, G., Bottini, A., Alquati, P., Matteis, A. D., Nuzzo, F., Giardina, G., Danese, S., Lena, M. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.012 · Cited by 84
(1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.2.305 · Cited by 83
Treatment for Anthracycline-Pretreated Metastatic Breast Cancer
O'Shaughnessy, J. A., Twelves, C. J., & Aapro, M. (2002) · The Oncologist · doi:10.1634/theoncologist.7-suppl_6-4 · Cited by 60
Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trial
Gundersen, S., Kvinnsland, S., Klepp, O., Kvaløy, S., Lund, E., & Høst, H. (1986) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(86)90075-1 · Cited by 56
Moinpour, C. M., Wu, J., Donaldson, G. W., Liepa, A. M., Melemed, A. S., O’Shaughnessy, J., Rappold, E., & Albain, K. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.621 · Cited by 51
Epirubicin or epirubicin and vindesine in advanced breast cancer. A Phase III study
Nielsen, D. L., Dombernowsky, P., Skovsgaard, T., Jensen, J. B., Andersen, E., Engelholm, S., & Hansen, M. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057748 · Cited by 27
Tashiro, H., Nomura, Y., & Ohsaki, A. (1994) · Japanese Journal of Clinical Oncology · doi:10.1093/oxfordjournals.jjco.a039708 · Cited by 22
Cited by
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
A New Era of Antibiotics: The Clinical Potential of Antimicrobial Peptides
Browne, K., Chakraborty, S., Chen, R., Willcox, M. D., Black, D. S., Walsh, W. R., & Kumar, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197047 · Cited by 482
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Metadata
- Authors
- Carrick, S., Parker, S., Thornton, C., Ghersi, D., Simes, J., & Wilcken, N.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-04-15
- Volume
- 2021
- Issue
- 5
- Pages
- CD003372-CD003372
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1500477185
- Cited by
- 305
- References
- 33
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.